Table 2.
Correlation between log-transformed (Ln) BPIFB4 levels and potentially informative variables in myocardial infarction patients.
| Ln BPIFB4 | |||||
|---|---|---|---|---|---|
| Variable | Obs | Value | N | Distribution/r | P |
| Three vessel CAD | 490 | No | 309 | 4.34 (3.54, 5.07) | 0.0077 |
| Yes | 181 | 4.04 (3.15, 4.78) | |||
| ANTHROPOMETRIC/DEMOGRAPHIC DATA | |||||
| Age | 492 | 492 | 0.06 [−0.03, 0.15] | 0.1904 | |
| Sex | 492 | No | 158 | 4.21 (3.25, 5.03) | 0.7583 |
| Yes | 334 | 4.24 (3.43, 5.04) | |||
| BMI (Kg/m2) | 490 | 490 | −0.02 [−0.11, 0.07] | 0.5930 | |
| RISK FACTORS AND COMORBIDITIES | |||||
| Anemia | 490 | No | 361 | 4.24 (3.42, 5.06) | 0.6128 |
| Yes | 129 | 4.2 (3.31, 4.94) | |||
| Chronic kidney disease | 490 | No | 444 | 4.22 (3.38, 5.05) | 0.7963 |
| Yes | 46 | 4.39 (3.34, 5) | |||
| Diabetes | 491 | No | 364 | 4.24 (3.29, 5.06) | 0.7410 |
| Yes | 127 | 4.2 (3.59, 4.92) | |||
| Dyslipidemia | 490 | No | 200 | 4.46 (3.59, 5.09) | 0.0127 |
| Yes | 290 | 4.11 (3.23, 5) | |||
| Hypertension | 490 | No | 138 | 4.31 (3.36, 5.02) | 0.8936 |
| Yes | 352 | 4.18 (3.38, 5.04) | |||
| Peripheral artery disease | 490 | No | 453 | 4.23 (3.36, 5.03) | 0.8425 |
| Yes | 37 | 4.24 (3.59, 5.08) | |||
| MI CLASSIFICATION AND RISK INDEXES | |||||
| Type | 489 | NSTEMI | 190 | 4.32 (3.4, 5.01) | 0.7885 |
| STEMI | 299 | 4.21 (3.37, 5.05) | |||
| Previous MI | 491 | No | 403 | 4.3 (3.45, 5.06) | 0.0787 |
| Yes | 88 | 3.88 (3.17, 4.76) | |||
| Family History for CAD | 489 | No | 375 | 4.26 (3.4, 5.06) | 0.4446 |
| Yes | 114 | 4.1 (3.36, 4.94) | |||
| NYHA class | 477 | 1 | 421 | 4.22 (3.42, 5.04) | 0.9427 |
| 2 | 40 | 4.23 (3.27, 4.9) | |||
| 3/4 | 16 | 4.33 (2.98, 5) | |||
| Killip classification > 1 | 491 | No | 372 | 4.2 (3.29, 5) | 0.1318 |
| Yes | 119 | 4.51 (3.58, 5.07) | |||
| GRACE score at 6 months | 489 | 489 | 0.1 [0.01, 0.19] | 0.0283 | |
| ECHOCARDIOGRAPHY AND LABORATORY TESTS | |||||
| LV Ejection Fraction | 476 | 476 | −0.06 [−0.15, 0.03] | 0.1921 | |
| HS CRP (mg/dL) | 474 | 474 | 0.04 [−0.05, 0.13] | 0.3564 | |
| MDRD (mL/min) | 480 | 480 | −0.03 [−0.12, 0.06] | 0.4794 | |
| Tnl max (ng/mL) | 481 | 481 | −0.01 [−0.1, 0.08] | 0.7540 | |
| TREATMENT | |||||
| Treatment | 480 | PCI | 343 | 4.2 (3.38, 4.98) | 0.1783 |
| CABG | 53 | 4.31 (3.29, 5.09) | |||
| Medical Therapy | 84 | 4.55 (3.59, 5.28) | |||
| ONGOING THERAPY | |||||
| ACE Inhibitors | 484 | No | 258 | 4.26 (3.37, 5.01) | 0.9680 |
| Yes | 226 | 4.14 (3.33, 5.06) | |||
| Beta Blockers | 485 | No | 349 | 4.25 (3.36, 5.01) | 0.7551 |
| Yes | 136 | 4.16 (3.43, 5.14) | |||
| Ca2+ Channel Blockers | 485 | No | 400 | 4.2 (3.41, 4.99) | 0.5230 |
| Yes | 85 | 4.48 (3.1, 5.24) | |||
| Nitrates | 484 | No | 426 | 4.27 (3.47, 5.06) | 0.0150 |
| Yes | 58 | 3.73 (3, 4.62) | |||
| Thiazide | 485 | No | 438 | 4.22 (3.28, 5) | 0.0985 |
| Yes | 47 | 4.26 (3.62, 5.32) | |||
| Loop diuretics | 485 | No | 441 | 4.24 (3.39, 5.06) | 0.3526 |
| Yes | 44 | 4.02 (3.06, 4.77) | |||
| Aldosterone antagonists | 485 | No | 471 | 4.23 (3.37, 5.04) | 0.9499 |
| Yes | 14 | 3.94 (3.26, 5.15) | |||
| Insulin | 485 | No | 458 | 4.23 (3.36, 5.04) | 0.9910 |
| Yes | 27 | 4.11 (3.48, 4.91) | |||
| Oral antidiabetic drugs | 486 | No | 405 | 4.22 (3.31, 5.03) | 0.3911 |
| Yes | 81 | 4.41 (3.66, 5.06) | |||
| Statins | 485 | No | 358 | 4.28 (3.37, 5.05) | 0.3663 |
| Yes | 127 | 4.01 (3.24, 5.01) | |||
| Allopurinol | 485 | No | 464 | 4.24 (3.37, 5.06) | 0.4797 |
| Yes | 21 | 4.01 (3.31, 4.75) | |||
| Aspirin | 485 | No | 338 | 4.27 (3.42, 5.06) | 0.2030 |
| Yes | 147 | 4.11 (3.24, 5.01) | |||
| Anti-platelet drugs | 485 | No | 443 | 4.25 (3.41, 5.05) | 0.1649 |
| Yes | 42 | 3.99 (3.1, 4.64) | |||
| Heparin | 485 | No | 466 | 4.24 (3.38, 5.06) | 0.2325 |
| Yes | 19 | 3.97 (3.09, 4.44) | |||
Total cohort included 492 patients, but data regarding the presence of three-vessel CAD was missing in 2 patients.
Variable analyzed variable, Obs. number of non-missing observations, Value value that each categorical/ordinal variable assumes, N number of observations, Distribution/r median (25th, 75th percentile) of Ln BPIFB4 distribution by categorical variables or Spearman correlation coefficient r [95% Confidence Interval] quantifying the degree of correlation between Ln BPIFB4 and numeric continuous/discrete variables, p value p value from Wilcoxon rank-sum test for independent samples comparing Ln BPIFB4 distribution between variables’ levels, from the Kruskal–Wallis test comparing Ln BPIFB4 distribution among variables’ levels, or from the Spearman correlation test. The reported variables had a frequency of missing values < 5% and were considered as potential confounders to be included in multivariate models (variables CAD duration, EDV, ESV, LV mass, E/A, BNP, HbA1C are excluded from the table for missing data fraction > 5%).